Spots Global Cancer Trial Database for serplulimab
Every month we try and update this database with for serplulimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | NCT05837052 | Unresectable Lu... | serplulimab plu... | 18 Years - 75 Years | Zhejiang University | |
| Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer | NCT06419673 | Cervical Cancer | Serplulimab Cisplatin Carboplatin Brachytherapy a... | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | NCT05766800 | Locally Advance... Non-small Cell ... | Serplulimab Carboplatin Pemetrexed Nab-paclitaxel Liposomal pacli... Surgery Radiotherapy | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | NCT06334757 | Non-Squamous No... | Serplulimab Bevacizumab Bio... Pemetrexed Carboplatin | 18 Years - 70 Years | Henan Cancer Hospital | |
| Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer | NCT05883670 | Cervical Cancer | Serplulimab | 18 Years - | Shandong University | |
| Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer | NCT05882513 | NSCLC Neoadjuvant The... | Serplulimab and... surgical resect... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | NCT06354218 | Esophageal Carc... | Serplulimab | 75 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC | NCT06350162 | Extensive Stage... | Serplulimab Chest Radiation | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City | |
| Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | NCT05585580 | Advanced Gastri... | Serplulimab Lenvatinib Paclitaxel/Pacl... | 18 Years - 75 Years | Qilu Hospital of Shandong University | |
| Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | NCT05918419 | Gastroesophagea... | Serplulimab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction | NCT05918419 | Gastroesophagea... | Serplulimab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City | |
| A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer | NCT05769725 | Serplulimab,Gas... | Serplulimab Docetaxel S1 | 18 Years - 75 Years | RenJi Hospital | |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | NCT05787613 | NSCLC Stage IV | HLX26 Serplulimab Chemotherapy dr... Placebo | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer | NCT05769725 | Serplulimab,Gas... | Serplulimab Docetaxel S1 | 18 Years - 75 Years | RenJi Hospital | |
| Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | NCT06368141 | Colon Cancer | Serplulimab Capecitabine Oxaliplatin | 18 Years - 75 Years | Ruijin Hospital | |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases | NCT05807893 | Non-small Cell ... Bevacizumab Immunotherapy Brain Metastase... | Serplulimab com... | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | NCT06368141 | Colon Cancer | Serplulimab Capecitabine Oxaliplatin | 18 Years - 75 Years | Ruijin Hospital | |
| Serplulimab Plus Chemotherapy for Early-stage ER+/HER2- Breast Cancer | NCT06394661 | Breast Cancer | Serplulimab | 18 Years - | Henan Cancer Hospital | |
| Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer | NCT05883670 | Cervical Cancer | Serplulimab | 18 Years - | Shandong University | |
| Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer | NCT05883670 | Cervical Cancer | Serplulimab | 18 Years - | Shandong University | |
| Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC | NCT06350162 | Extensive Stage... | Serplulimab Chest Radiation | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) | NCT05732493 | Locally Advance... | Serplulimab short-term radi... Oxaliplatin Capecitabine | 18 Years - | Fudan University | |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases | NCT05807893 | Non-small Cell ... Bevacizumab Immunotherapy Brain Metastase... | Serplulimab com... | 18 Years - 75 Years | Sun Yat-sen University | |
| Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases | NCT05894837 | Colorectal Canc... Liver Metastase... | Serplulimab+Reg... Hepatic Artery ... | 18 Years - | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | NCT05975749 | Gastric Cancer | Serplulimab Trastuzuma Chemotherapy | 20 Years - 80 Years | Fudan University | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. | NCT06195683 | Non-small Cell ... PDL1 Gene Mutat... | Serplulimab | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma | NCT06422858 | Locally Advance... | Serplulimab Tegafur-gimerac... Radiotherapy Cisplatin | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC | NCT05765825 | Extensive-stage... | serplulimab Cisplatin Carboplatin Etoposide Thoracic radiat... | 18 Years - | Sichuan University | |
| Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | NCT06128252 | Gastric Cancer | Taurine Serplulimab XELOX regimen FLOT regimen | 18 Years - 75 Years | Tang-Du Hospital | |
| Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | NCT05585580 | Advanced Gastri... | Serplulimab Lenvatinib Paclitaxel/Pacl... | 18 Years - 75 Years | Qilu Hospital of Shandong University | |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | NCT06334757 | Non-Squamous No... | Serplulimab Bevacizumab Bio... Pemetrexed Carboplatin | 18 Years - 70 Years | Henan Cancer Hospital | |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | NCT05731726 | pMMR MSS MSI-L Locally Advance... | Serplilumab Capecitabine Oxaliplatin Celecoxib | 18 Years - 75 Years | Zhejiang University | |
| Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma | NCT06422858 | Locally Advance... | Serplulimab Tegafur-gimerac... Radiotherapy Cisplatin | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | NCT06364046 | Carcinoma Small Cell Lung... | Drug-eluting be... Serplulimab Intravenous che... | 18 Years - | The Central Hospital of Lishui City | |
| Serplulimab Combined With CCRT for LS-SCLC. | NCT06295926 | Small Cell Lung... | Serplulimab | 18 Years - | Peking Union Medical College Hospital | |
| Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer | NCT05975749 | Gastric Cancer | Serplulimab Trastuzuma Chemotherapy | 20 Years - 80 Years | Fudan University | |
| Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) | NCT05872685 | Adenocarcinoma ... Adenocarcinoma ... Proficient Mism... | S1 Oxaliplatin Serplulimab Placebo | 18 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC | NCT05765825 | Extensive-stage... | serplulimab Cisplatin Carboplatin Etoposide Thoracic radiat... | 18 Years - | Sichuan University | |
| Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | NCT05659251 | Esophageal Squa... Neoadjuvant The... | Serplulimab, Al... Esophagectomy sample | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | NCT05731726 | pMMR MSS MSI-L Locally Advance... | Serplilumab Capecitabine Oxaliplatin Celecoxib | 18 Years - 75 Years | Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
